| scholarly article | Q13442814 |
| P50 | author | Bruno P A Cammue | Q88085635 |
| Karin Thevissen | Q38319981 | ||
| P2093 | author name string | Tanne L Cools | |
| Paul Cos | |||
| Kaat De Cremer | |||
| Katrijn De Brucker | |||
| Ellen Lanckacker | |||
| Marijke Bax | |||
| P2860 | cites work | Review of the toxicity of hexachlorophene, including its neurotoxicity | Q39880485 |
| Combinatory effect of fluconazole and FDA-approved drugs against Candida albicans | Q42257229 | ||
| Fluconazole-resistant Candida albicans vulvovaginitis | Q42285758 | ||
| Adaptive response to the antimalarial drug artesunate in yeast involves Pdr1p/Pdr3p-mediated transcriptional activation of the resistance determinants TPO1 and PDR5. | Q42505217 | ||
| In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis. | Q42727587 | ||
| Fungicidal activity of miconazole against Candida spp. biofilms | Q43174722 | ||
| Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole | Q46841148 | ||
| Propensity for biofilm formation by clinical isolates from urinary tract infections: developing a multifactorial predictive model to improve antibiotherapy. | Q46945760 | ||
| Optimization of resazurin-based viability staining for quantification of microbial biofilms | Q49099206 | ||
| Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. | Q50509935 | ||
| Artemisinins act through at least two targets in a yeast model. | Q52608025 | ||
| The Yak1p kinase controls expression of adhesins and biofilm formation in Candida glabrata in a Sir4p-dependent pathway. | Q53872317 | ||
| Oral candidosis: characterization of a sample of recurrent infections and study of resistance determinants. | Q54545294 | ||
| Synergy, antagonism, and what the chequerboard puts between them | Q73521098 | ||
| Yeast model uncovers dual roles of mitochondria in action of artemisinin | Q21145281 | ||
| Pumped up: reflections on PfATP6 as the target for artemisinins | Q22061938 | ||
| Mechanisms of Candida biofilm drug resistance | Q26827521 | ||
| Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms | Q26861656 | ||
| Multidrug tolerance of biofilms and persister cells | Q33331522 | ||
| Candida and invasive candidiasis: back to basics. | Q33351140 | ||
| Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation | Q33539757 | ||
| Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms | Q33843060 | ||
| Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole | Q33939052 | ||
| Isogenic strain construction and gene mapping in Candida albicans. | Q33961115 | ||
| Antibiotics in the clinical pipeline in 2011. | Q34185670 | ||
| Oral candidosis--clinical challenges of a biofilm disease | Q34202383 | ||
| Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital | Q34221581 | ||
| Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients | Q34394677 | ||
| Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. | Q34528828 | ||
| Absorption of pyrvinium pamoate | Q34532756 | ||
| Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection | Q34633796 | ||
| High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors | Q34729487 | ||
| Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. | Q35055832 | ||
| Importance of Candida-bacterial polymicrobial biofilms in disease | Q35490098 | ||
| Fungal biofilm resistance | Q35821475 | ||
| Potentiation of azole antifungals by 2-adamantanamine | Q37036494 | ||
| The molecular mechanism of action of artemisinin--the debate continues. | Q37718570 | ||
| The clinical importance of fungal biofilms. | Q38114168 | ||
| Iron and heme metabolism in Plasmodium falciparum and the mechanism of action of artemisinins | Q38127988 | ||
| Management of infections related to totally implantable venous-access ports: challenges and perspectives | Q38169327 | ||
| Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole | Q38283148 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Candida albicans | Q310443 |
| artemisinin | Q426921 | ||
| biofilm | Q467410 | ||
| P304 | page(s) | 421-426 | |
| P577 | publication date | 2014-11-03 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms | |
| P478 | volume | 59 |
| Q96304676 | Combination of Antifungal Drugs and Protease Inhibitors Prevent Candida albicans Biofilm Formation and Disrupt Mature Biofilms |
| Q38526460 | Combinatorial drug approaches to tackle Candida albicans biofilms |
| Q92922412 | Cytotoxic Action of Artemisinin and Scopoletin on Planktonic Forms and on Biofilms of Candida Species |
| Q46427960 | DS6: anticandidal, antibiofilm peptide against Candida tropicalis and exhibit synergy with commercial drug. |
| Q91793517 | Efficacy of Artesunate against Pseudomonas aeruginosa Biofilm Mediated by Iron |
| Q92525201 | High Efficiency Drug Repurposing Design for New Antifungal Agents |
| Q57789673 | Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the Quorum-Sensing System of Pseudomonas aeruginosa |
| Q64084323 | Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen |
| Q48310145 | In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis. |
| Q55511181 | Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. |
| Q57705351 | Recent Advancements in Combinational Antifungal Therapy and Immunotherapy |
| Q94554889 | Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species |
| Q91899329 | Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study |
| Q57705350 | Review on fungal enzyme inhibitors – potential drug targets to manage human fungal infections |
| Q36974985 | Stimulation of superoxide production increases fungicidal action of miconazole against Candida albicans biofilms |
| Q28547086 | Synergistic Activity of the Plant Defensin HsAFP1 and Caspofungin against Candida albicans Biofilms and Planktonic Cultures |
| Q64928954 | Zinc and Iron Homeostasis: Target-Based Drug Screening as New Route for Antifungal Drug Development. |
Search more.